Texas Clinical Trials Report — April 2026

For Texans considering participation in clinical research, April 2026 presents a crucial window of opportunity, particularly for those looking to join studies that are nearing their enrollment deadlines. Across the state, a significant 353 clinical trials are slated to close within the next 90 days. This urgency extends to healthy volunteers, with 47 of these rapidly closing studies actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly before they are no longer available.

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on various cancers, heart conditions, and inflammatory diseases are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Advanced solid tumor
• Acute myeloid leukemia
• Coronary artery disease
• Non-small cell lung cancer
• Heart failure
• Bladder cancer
• Myelodysplastic syndromes
• Atopic dermatitis
• Amyotrophic lateral sclerosis
• Metastatic cancer

Major Research Initiatives Launch Across Texas

This month brings several high-profile new trials to Texas, including significant Phase 2 and 3 studies from major pharmaceutical companies and leading academic institutions. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic tools, addressing a range of health challenges from metabolic disorders to advanced cancers and public health concerns.

• Novo Nordisk A/S is launching two notable Phase 3 studies:
  • NCT07533175, "AMAZE 2," is investigating how well the medicine NNC0487-0111 helps people with excess body weight and Type 2 diabetes lose weight. This large trial aims to enroll 630 participants to evaluate the safety and effectiveness of this weekly injectable treatment.
  • NCT07509307, "AMAZE 6," is also investigating NNC0487-0111, but for people with excess body weight and knee osteoarthritis, focusing on weight loss and pain reduction. This study plans for 400 participants.
• Incyte Corporation is sponsoring NCT07522073, a Phase 3 study evaluating chemotherapy with or without INCB161734 in previously untreated, KRAS G12D-Mutated metastatic pancreatic ductal adenocarcinoma. This important oncology trial seeks 588 participants.
• Kinaset Therapeutics Inc. is initiating NCT07532265, a Phase 2 dose-ranging clinical study to evaluate the efficacy and safety of Frevecitinib (KN-002) in patients with severe asthma not controlled by standard treatments. This study is designed for 512 participants.
• Priovant Therapeutics, Inc. is conducting NCT07532603, a Phase 2/3 study of Brepocitinib in adults with lichen planopilaris, evaluating the clinical safety and efficacy of this oral treatment for 342 participants.
• Caliway Biopharmaceuticals Co., Ltd. is sponsoring NCT07526974, a Phase 3 study (SUPREME-02) to evaluate the efficacy and safety of CBL-514 injection for reducing subcutaneous fat. This randomized, double-blinded, placebo-controlled study targets 320 participants.
• Beyond drug development, Texas Christian University is leading NCT07528846, the "Justice Community Overdose Innovation Network II TCU Hub," a large implementation research study involving 1,620 participants to enhance understanding of public health and public safety outcomes related to overdose and substance use.
• The University of Texas Health Science Center, Houston, is sponsoring NCT07525076, a study focused on implementing an opt-out testing and rapid diagnostic strategy for Syphilis and HIV in pregnant patients presenting to the Emergency Department, aiming to enroll 1,400 participants.

April's Research Landscape: New Opportunities and Geographic Reach

This month, Texas saw the opening of 44 new clinical trials, a decrease from the 80 trials that launched in March 2026. Despite this dip, the state continues to offer a diverse array of research opportunities, with a total of 4,817 clinical trials currently recruiting across 178 cities and 4,350 research sites.

The vast majority of new research initiatives this month are concentrated in Texas's major metropolitan centers. Houston leads with 18 new trials, followed by Dallas with 9, and San Antonio with 8. Other cities with new trials include:

• Fort Worth (4)
• Austin (3)
• Galveston (2)
• Plano (2)
• Denison (1)
• Humble (1)
• Irving (1)

This distribution highlights that while opportunities exist statewide, the most concentrated activity for new research is found in the larger urban areas.

New studies are exploring a range of conditions, from common ailments to more specialized areas. This month's new trials are targeting:

• Overweight
• Obesity
• Alopecia areata
• Atypical teratoid rhabdoid tumor
• Autism spectrum disorder (multiple trials)
• Central nervous system rhabdoid tumor

The types of interventions being studied are varied, with drug trials leading the way, accounting for 25 of the new trials. Other trial types include 9 "OTHER" studies, 6 device trials, 3 biological trials, 2 procedure-based studies, 1 dietary supplement trial, and 1 diagnostic test trial.

Diverse Participation: Healthy Volunteers and Specific Demographics

Participation in clinical trials is open to a wide range of individuals. Of the 44 new trials launched this month, 34 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 8 new trials are open to children, 2 are specifically for female participants, and 1 is for male participants.

For individuals without a specific medical condition, there are significant opportunities to contribute. 10 of the new trials this month are actively seeking healthy volunteers. Across Texas, a total of 512 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Academic institutions and major medical centers continue to play a vital role in Texas's research ecosystem, with M.D. Anderson Cancer Center sponsoring 9 of the new trials. Other notable academic sponsors include Baylor Research Institute and Baylor College of Medicine, each sponsoring 2 new trials. Industry sponsors, including Novo Nordisk A/S, Eli Lilly and Company, Incyte Corporation, and Mead Johnson Nutrition, are also driving significant research efforts. Overall, 20 new trials are industry-sponsored, while 22 fall under "OTHER" (often academic or institutional), 1 is federally funded, and 1 is sponsored by the NIH.

Looking ahead, the focus will likely remain on the ongoing enrollment in these significant Phase 2 and 3 trials, while researchers across Texas prepare for the next wave of innovative studies to address a broad spectrum of health challenges.